Achillion Pharmaceuticals (NASDAQ:ACHN) was upgraded by investment analysts at Maxim Group from a “hold” rating to a “buy” rating in a note issued to investors on Monday, TheFlyOnTheWall.com reports. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares after opening at $3.69 moved to $3.83 on last trade day and at the end of the day closed at $3.43. Company price to sales ratio in past twelve months was calculated as and price to cash ratio as 2.37. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) showed a negative weekly performance of -0.87%.
Leerink raised its price target for Insmed Incorporated (NASDAQ:INSM) shares to $30 saying it continues to be “very encouraged” by the 11 culture conversions observed in Arikayce for the treatment of non-tuberuclous mycobacteria. The firm reiterates an Outperform rating on the stock following the company’s conference call. Insmed Incorporated (NASDAQ:INSM) advanced/fell -13.09% in last trading session and ended the day on $15.90. return on equity ratio is recorded as -43.70% and its return on assets is -34.60%. Insmed Incorporated (NASDAQ:INSM) yearly performance is 112.63%.
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) a developer of new drugs to treat gastrointestinal disorders and diseases, reported its financial results and business update for the fourth quarter and the year ended December 31, 2013. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares moved down -8.03% in last trading session and was closed at $5.27 while trading in range of $5.22 – $5.88 – Synergy Pharmaceuticals Inc (NASDAQ:SGYP) year to date (YTD) performance is -5.05%.
Stock in Idera Pharmaceuticals (NASDAQ:IDRA) tanked this week when Celgene announced that the FDA approved Otezla (apremilast) for psoriatic arthritis, a major competitor of Idera’s Phase II candidate, IMO-8400. Idera Pharmaceuticals Inc (NASDAQ:IDRA) weekly performance is -36.42%. On last trading day company shares ended up $4.19. Idera Pharmaceuticals Inc (NASDAQ:IDRA) distance from 50-day simple moving average (SMA50) is -18.35%. Analysts mean target price for the company is $7.00.